ZA200209087B - Use of lactobacillus casei in immunostimulatory peptides. - Google Patents

Use of lactobacillus casei in immunostimulatory peptides.

Info

Publication number
ZA200209087B
ZA200209087B ZA200209087A ZA200209087A ZA200209087B ZA 200209087 B ZA200209087 B ZA 200209087B ZA 200209087 A ZA200209087 A ZA 200209087A ZA 200209087 A ZA200209087 A ZA 200209087A ZA 200209087 B ZA200209087 B ZA 200209087B
Authority
ZA
South Africa
Prior art keywords
lactobacillus casei
immunostimulatory peptides
immunostimulatory
peptides
casei
Prior art date
Application number
ZA200209087A
Other languages
English (en)
Inventor
Eric Postaire
Benjamin Bonavida
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200209087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of ZA200209087B publication Critical patent/ZA200209087B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/125Casei
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/245Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200209087A 2000-05-25 2002-11-08 Use of lactobacillus casei in immunostimulatory peptides. ZA200209087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006679A FR2809312B1 (fr) 2000-05-25 2000-05-25 Utilisation de l. casei dans des compositions immunostimulantes

Publications (1)

Publication Number Publication Date
ZA200209087B true ZA200209087B (en) 2004-06-30

Family

ID=8850597

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209087A ZA200209087B (en) 2000-05-25 2002-11-08 Use of lactobacillus casei in immunostimulatory peptides.

Country Status (28)

Country Link
US (1) US7604809B2 (de)
EP (1) EP1283714B1 (de)
JP (1) JP2003534284A (de)
CN (1) CN1194707C (de)
AR (1) AR028626A1 (de)
AT (1) ATE332143T1 (de)
AU (2) AU2001256435B2 (de)
BG (1) BG65884B1 (de)
BR (1) BR0111135A (de)
CA (1) CA2410350C (de)
CZ (1) CZ303600B6 (de)
DE (1) DE60121327T2 (de)
DK (1) DK1283714T3 (de)
EA (1) EA005081B1 (de)
ES (1) ES2267763T3 (de)
FR (1) FR2809312B1 (de)
HK (1) HK1055898A1 (de)
HR (1) HRP20020935A2 (de)
HU (1) HUP0302041A3 (de)
IL (1) IL152980A0 (de)
MA (1) MA25760A1 (de)
MX (1) MXPA02011636A (de)
NO (1) NO332369B1 (de)
PL (1) PL201801B1 (de)
PT (1) PT1283714E (de)
SK (1) SK18272002A3 (de)
WO (1) WO2001089541A1 (de)
ZA (1) ZA200209087B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en) 2000-04-15 2000-05-31 Sec Dep For The Home Departmen Improvements in and relating to analysis of DNA samples
US9610347B2 (en) * 2001-04-30 2017-04-04 Cortcontrol Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) * 2003-05-30 2007-05-23 上海光明乳业股份有限公司 干酪乳杆菌Bd-II菌株及其在降低血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1629850B2 (de) * 2004-08-24 2013-05-22 N.V. Nutricia Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält
ZA200705844B (en) * 2004-12-15 2008-09-25 Van Der Westhuzen Corne Floris Detoxifying and immunity-booster composition
EP1683425A1 (de) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Verwendung von fermentiertem Milchprodukt enthaltend L. Casei zur Herstellung eines Zusammensetzung zur Prävention oder Behandlung Überempfindlichkeitsreaktionen vom verzögerten Typ
ES2264368B1 (es) * 2005-02-11 2007-12-01 Francisco Exposito Mesa Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
EP1885383B1 (de) 2005-05-31 2016-09-21 IAMS Europe B.V. Katzen probiotisches bifidobacterium
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
NZ575974A (en) 2006-09-10 2012-03-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
CA2722738C (en) * 2008-05-13 2017-04-25 Glycotope Gmbh Fermentation process
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2153837A1 (de) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Zusammensetzungen mit Lactobacillus casei zur Verbesserung der Resistenz gegen verbreitete Infektionskrankheiten
FR2937252B1 (fr) 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2521769B1 (de) * 2010-01-08 2016-05-18 Compagnie Gervais Danone Milchsäurebakterien mit antioxidierender wirkung
BR112012023028B1 (pt) * 2010-03-12 2020-12-08 Compagnie Gervais Danone meio fermentado por uma cepa de bactéria de ácido láctico, composição e seu uso
EP2627198B1 (de) * 2010-10-15 2015-09-02 Chr. Hansen A/S Immunadjuvans
EP2455092A1 (de) * 2010-11-11 2012-05-23 Nestec S.A. Nicht replizierende probiotische Mikroorganismen als Schutz vor Infektionen der oberen Atemwege
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
SI3794042T1 (sl) 2018-05-18 2024-07-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236872A (ja) * 1992-02-27 1993-09-17 Takanashi Nyugyo Kk 乳酸菌含有食品
JP4112021B2 (ja) * 1994-02-16 2008-07-02 明治乳業株式会社 乳酸菌を用いた免疫賦活剤
ES2126962T3 (es) * 1995-01-02 1999-04-01 Gervais Danone Co Fermento lactico, y su uso para la preparacion de productos antidiarreicos.
JP3694236B2 (ja) * 1997-08-21 2005-09-14 ニュージーランド デアリー ボード 免疫増強作用を有する乳酸菌
US6699517B2 (en) * 1997-11-28 2004-03-02 Compagnie Gervais Danone Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품

Also Published As

Publication number Publication date
NO20025595L (no) 2003-01-22
MXPA02011636A (es) 2003-05-14
EA005081B1 (ru) 2004-10-28
PL201801B1 (pl) 2009-05-29
DE60121327T2 (de) 2007-07-26
HUP0302041A2 (hu) 2003-09-29
FR2809312B1 (fr) 2002-07-12
IL152980A0 (en) 2003-06-24
PT1283714E (pt) 2006-11-30
US7604809B2 (en) 2009-10-20
EP1283714A1 (de) 2003-02-19
PL358408A1 (en) 2004-08-09
CA2410350A1 (fr) 2001-11-29
AU5643501A (en) 2001-12-03
CZ303600B6 (cs) 2013-01-02
NO332369B1 (no) 2012-09-03
ES2267763T3 (es) 2007-03-16
DE60121327D1 (de) 2006-08-17
AU2001256435B2 (en) 2006-06-29
CA2410350C (fr) 2013-04-09
DK1283714T3 (da) 2006-10-30
CN1194707C (zh) 2005-03-30
BG107299A (bg) 2003-07-31
BG65884B1 (bg) 2010-04-30
WO2001089541A1 (fr) 2001-11-29
EP1283714B1 (de) 2006-07-05
MA25760A1 (fr) 2003-04-01
FR2809312A1 (fr) 2001-11-30
BR0111135A (pt) 2003-04-08
HUP0302041A3 (en) 2005-11-28
NO20025595D0 (no) 2002-11-21
HRP20020935A2 (en) 2005-02-28
JP2003534284A (ja) 2003-11-18
HK1055898A1 (en) 2004-01-30
SK18272002A3 (sk) 2003-08-05
ATE332143T1 (de) 2006-07-15
AR028626A1 (es) 2003-05-14
CZ20024189A3 (cs) 2003-05-14
US20040029127A1 (en) 2004-02-12
EA200201248A1 (ru) 2003-06-26
CN1430518A (zh) 2003-07-16

Similar Documents

Publication Publication Date Title
ZA200209087B (en) Use of lactobacillus casei in immunostimulatory peptides.
AU2001256435A1 (en) Use of lactobacillus casei in immunostimulatory compositions
IL160050A0 (en) Probiotic lactobacillus casei strains
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
AU7616001A (en) Probiotic recolonisation therapy
TWI317737B (en) Membrane penetrating peptides and uses thereof
AU6079201A (en) Lactobacillus reuteri glucosyltransferase
HUP0600031A2 (en) Kahalalide formulations and their use
AU2001254856A1 (en) Lactococcus lactis genome, polypeptides and uses
EP1343819A4 (de) Hla-a2.1- bindungspeptide und ihre verwendung
GB0026134D0 (en) Peptides and their use
SG97174A1 (en) Lactobacillus rhamnosus strain and uses thereof
EP1275659A4 (de) Physiologisch aktive peptide und anwendung derselben
HUP0300489A3 (en) Novel protein and gene encoding the same
IL145527A0 (en) Retro-inverso prosaposin-derived peptides and use thereof
EP1300416A4 (de) Gedächtnisverstärkende peptide und deren verwendung(16.01.02)
GB0026136D0 (en) Peptides and their use
GB0018148D0 (en) Peptides and their use
GB0017028D0 (en) Peptides and their therapeutic use
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
AU5995701A (en) Synthetic peptides and uses therefore
GB0002563D0 (en) Virulence gene and protein and their use
GB0003725D0 (en) Virulence gene and protein and their use
GB0002555D0 (en) Virulence gene and protein and their use